- Home
- HCKT vs BCYC Comparison
HCKT vs BCYC Comparison
Compare HCKT & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCKT | BCYC |
|---|---|---|
| Founded | 1991 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.0M | 360.7M |
| IPO Year | 1998 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HCKT | BCYC |
|---|---|---|
| Price | $13.85 | $4.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $17.00 | ★ $17.56 |
| AVG Volume (30 Days) | ★ 343.8K | 333.2K |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.40% | N/A |
| EPS Growth | N/A | ★ 42.91 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $285,862,000.00 | N/A |
| Revenue This Year | $2.55 | N/A |
| Revenue Next Year | $5.07 | N/A |
| P/E Ratio | $30.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.76 | $5.00 |
| 52 Week High | $29.52 | $10.13 |
Technical Indicators
Market Signals| Indicator | HCKT | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 39.18 | 30.87 |
| Support Level | $12.76 | N/A |
| Resistance Level | $21.13 | $7.71 |
| Average True Range (ATR) | 0.51 | 0.27 |
| MACD | 0.20 | -0.03 |
| Stochastic Oscillator | 44.39 | 0.00 |
Price Performance
Historical ComparisonAbout HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.